A Randomized Study to Compare Bioactive Titanium Stents and Everolimus-eluting Stents in Diabetic Patients (TITANIC XV): 1-year Results
| Autor: | José R, López-Mínguez, Juan M, Nogales-Asensio, Luis J, Doncel-Vecino, Antonio, Merchán-Herrera, Francisco, Pomar-Domingo, Pedro, Martínez-Romero, José A, Fernández-Díaz, Raúl, Valdesuso-Aguilar, José, Moreu-Burgos, José, Díaz-Fernández, Pasi, Karjalainen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Target lesion medicine.medical_specialty medicine.medical_treatment Revascularization Coronary Restenosis Diabetes Complications Restenosis Internal medicine medicine Humans Everolimus Myocardial infarction Stroke Aged Sirolimus Titanium business.industry Stent Percutaneous coronary intervention Drug-Eluting Stents General Medicine Middle Aged medicine.disease Cardiology Female Stents business Immunosuppressive Agents medicine.drug |
| Zdroj: | Revista Española de Cardiología (English Edition). 67:522-530 |
| ISSN: | 1885-5857 |
| Popis: | Up to 25% of patients who undergo a percutaneous coronary intervention show some limitation in the use of drug-eluting stents. The aim of this study was to evaluate if titanium-nitride-oxide-coated stents could be a good alternative to everolimus-eluting stents in diabetic patients.A total of 173 diabetic patients with lesions at moderate risk of restenosis (exclusion criteria: diameter2.5 mm or length28 mm in vessels3mm, chronic occlusion) were randomized to a titanium group (83 patients) or an everolimus group (90 patients).Baseline characteristics were well balanced; 28.3% of patients were insulin dependent. At 1 year, the incidence of major adverse cardiac events (death, nonfatal myocardial infarction, stroke, or repeat target vessel revascularization) was significantly higher in the titanium group than in the everolimus group (total, 14.5% vs 4.4%; P = .02; noninsulin-dependent subgroup, 9.7% vs 3.2%; P = .14; insulin-dependent subgroup, 28.6% vs 7.1%; P = .04). The incidence of death, nonfatal myocardial infarction, stroke, or any revascularization was 16.9% in the titanium group and 7.8% in the everolimus group (P = .06). Target lesion and vessel revascularizations occurred in 8.4% compared with 3.3% (P = .15) and in 13.3% compared with 3.3% (P = .01) in the titanium and everolimus groups, respectively. Angiographic follow-up at 9 months showed significantly less late lumen loss in the everolimus group (in-segment, 0.52 [standard deviation, 0.58) mm vs -0.05 [0.32] mm; in-stent, 0.76 [0.54] mm vs 0.13 [0.31] mm; P.0001).The everolimus-eluting stent is superior to the titanium stent for clinical and angiographic end points in diabetic patients with lesions at moderate risk of restenosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect